文献速递肿瘤 PET/CT神经核医学

「68Ga」Ga-生长抑素受体PET/CT在肺神经内分泌(类癌)肿瘤分级及播散性疾病检测中的价值:单中心基于病理的分析与文献综述

Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature.
PubMed 文献 · EJNMMI Res · 2022-05-07

该单中心回顾性分析纳入86例肺类癌患者的86次SSTR PET/CT,其中46例有「18F」FDG PET/CT。原发瘤SSTR摄取在典型类癌显著高于非典型类癌(中位SUVmax 18.4 vs 3.8,p=0.003),「18F」FDG摄取在非典型类癌显著高于典型类癌(中位SUVmax 5.4 vs 3.5,p=0.038)。SSTR PET/CT对典型类癌淋巴结转移诊断AUC为0.91,在12个病理证实的远处转移灶中PPV为100%。

要点

  • 典型类癌原发瘤SSTR摄取显著高于非典型类癌(中位SUVmax 18.4 vs 3.8,p=0.003)。
  • 非典型类癌「18F」FDG摄取显著高于典型类癌(中位SUVmax 5.4 vs 3.5,p=0.038)。
  • SSTR PET/CT对典型类癌淋巴结转移诊断AUC为0.91,高于「18F」FDG PET/CT的0.74,但差异未达统计学显著(p=0.10)。

核心结论

  • 研究证实典型类癌的SSTR配体摄取高于非典型类癌,「18F」FDG摄取则相反。
  • SSTR PET/CT对典型类癌肺门和纵隔淋巴结转移有良好的诊断效能。
  • 在因SSTR PET/CT可疑而经病理检查的12个远处转移灶中,SSTR PET/CT的阳性预测值为100%。
  • 综合来看,SSTR PET/CT在肺类癌的TNM评估中具有很高的诊断价值,尤其在典型类癌中,这强调了其在欧洲指南中的地位。

研究设计与样本

  • 单中心基于病理的回顾性分析,纳入2007年1月至2020年5月期间因肺类癌行SSTR PET/CT的86例患者的86次扫描。
  • 其中46例患者有可用的「18F」FDG PET/CT图像。
  • 记录原发肿瘤、经病理检查的肺门和纵隔淋巴结站及远处转移灶的最大标准化摄取值(SUVmax)。
  • 对SSTR和「18F」FDG PET/CT的肿瘤SUVmax与肿瘤类型(典型类癌 vs 非典型类癌)进行关联分析。
  • 对淋巴结SUVmax与病理状态(N+ vs N-)进行比较,并对所有病理证实的远处转移灶进行混合模型分析。

主要发现

  • 原发肿瘤SSTR摄取在典型类癌显著高于非典型类癌(中位SUVmax 18.4 vs 3.8;p=0.003)。
  • 原发肿瘤「18F」FDG摄取在非典型类癌显著高于典型类癌(中位SUVmax 5.4 vs 3.5;p=0.038)。
  • SSTR PET/CT检测典型类癌的ROC曲线AUC为0.78;「18F」FDG PET/CT检测非典型类癌的AUC为0.73。
  • 在83个淋巴结站中,SSTR PET/CT检测典型类癌淋巴结转移的AUC为0.91,「18F」FDG PET/CT为0.74(差值0.17;95%CI -0.03至0.38;p=0.10)。
  • 在10例患者12个因SSTR PET/CT可疑而经病理检查的远处病灶中,阳性预测值为100%。

关键数值与推荐

  • 典型类癌 vs 非典型类癌原发瘤SSTR中位SUVmax:18.4 vs 3.8(p=0.003)。
  • 非典型类癌 vs 典型类癌原发瘤「18F」FDG中位SUVmax:5.4 vs 3.5(p=0.038)。
  • SSTR PET/CT检测典型类癌的AUC为0.78;「18F」FDG PET/CT检测非典型类癌的AUC为0.73。
  • SSTR PET/CT检测典型类癌淋巴结转移AUC为0.91,「18F」FDG PET/CT为0.74(差值0.17;95%CI -0.03至0.38;p=0.10)。
  • SSTR PET/CT在12个病理检查的远处转移灶中阳性预测值为100%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although most guidelines suggest performing a positron emission tomography/computed tomography (PET/CT) with somatostatin receptor (SSTR) ligands for staging of pulmonary carcinoid tumours (PC), only a limited number of studies have evaluated the role of this imaging tool in this specific patient population. The preoperative differentiation between typical carcinoid (TC) and atypical carcinoid (AC) and the extent of dissemination (N/M status) are crucial factors for treatment allocation and prognosis of these patients. Therefore, we performed a pathology-based retrospective analysis of the value of SSTR PET/CT in tumour grading and detection of nodal and metastatic involvement of PC and compared this with the previous literature and with [18F]FDG PET/CT in a subgroup of patients. METHODS: SSTR PET/CT scans performed between January 2007 and May 2020 in the context of PC were included. If available, [18F]FDG PET/CT images were also evaluated. The maximum standardized uptake (SUVmax) values of the primary tumour, of the pathologically examined hilar and mediastinal lymph node stations, as well as of the distant metastases, were recorded. Tumoural SUVmax values were related to the tumour type (TC versus AC) for both SSTR and [18F]FDG PET/CT in diagnosing and differentiating both tumour types. Nodal SUVmax values were compared to the pathological status (N+ versus N-) to evaluate the diagnostic accuracy of SSTR PET/CT in detecting lymph node involvement. Finally, a mixed model analysis of all pathologically proven distant metastatic lesions was performed. RESULTS: A total of 86 SSTR PET/CT scans performed in 86 patients with PC were retrospectively analysed. [18F]FDG PET/CT was available in 46 patients. Analysis of the SUVmax values in the primary tumour showed significantly higher SSTR uptake in TC compared with AC (median SUVmax 18.4 vs 3.8; p = 0.003) and significantly higher [18F]FDG uptake in AC compared to TC (median SUVmax 5.4 vs 3.5; p = 0.038). Receiver operating characteristic (ROC) curve analysis resulted in an area under the curve (AUC) of 0.78 for the detection of TC on SSTR PET/CT and of 0.73 for the detection of AC on [18F]FDG PET/CT. A total of 267 pathologically evaluated hilar and mediastinal lymph node stations were analysed. ROC analysis of paired SSTR/[18F]FDG SUVmax values for the detection of metastasis of TC in 83 lymph node stations revealed an AUC of 0.91 for SSTR PET/CT and of 0.74 for [18F]FDG PET/CT (difference 0.17; 95% confidence interval - 0.03 to 0.38; p = 0.10). In a sub-cohort of 10 patients with 12 distant lesions that were pathologically examined due to a suspicious aspect on SSTR PET/CT, a positive predictive value (PPV) of 100% was observed. CONCLUSION: Our findings confirm the higher SSTR ligand uptake in TC compared to AC and vice versa for [18F]FDG uptake. More importantly, we found a good diagnostic performance of SSTR PET/CT for the detection of hilar and mediastinal lymph node metastases of TC. Finally, a PPV of 100% for SSTR PET/CT was found in a small sub-cohort of patients with pathologically investigated distant metastatic lesions. Taken together, SSTR PET/CT has a very high diagnostic value in the TNM assessment of pulmonary carcinoids, particularly in TC, which underscores its position in European guidelines.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Deleu AL, Laenen A, Decaluwé H, et al. Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature. EJNMMI Res. 2022. PMID: 35524900. doi:10.1186/s13550-022-00900-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。